Fundraising Fox
Avidity Biosciences
La Jolla, US · Founded 2012 · 425 employees on LinkedIn · 5 known investors
Find your way into Avidity Biosciences
Sign up to see every warm intro you have to Avidity Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Avidity Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases. The company has three clinical-stage programs targeting myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.
Founders & leadership
Avidity Biosciences was founded in 2012 by Troy Wilson PhD., JD, P. Kent Hawryluk, Mark E. Davis, and Troy Wilson.
Board
Investors · 5
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: Brace Pharma's portfolio page · Not right? Tell us
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$527.8M disclosed across 4 of 6 rounds · 2014–2025
- Undisclosed amountfollow-on public offeringSep 2025Source ↗
▶$400.2MraisedMar 2024 · 45 investors · BiotechnologyRule 506(b)
- Noreen HenigDirector
- Carsten BoessDirector
- Troy WilsonDirector
- Tamar ThompsonDirector
- Sarah BoyceExecutive Officer, Director
- Teresa McCarthyExecutive Officer
- Edward KayeDirector
- Jean KimDirector
- W. Michael FlanaganExecutive Officer
- Arthur LevinExecutive Officer
- Michael MacLeanExecutive Officer
- Offering amount
- $400.2M
- Amount sold
- $400.2M
- Sales commissions
- $20M
- Placement agents
- Chardan Capital Markets, LLC, BofA Securities Inc., Leerink Partners LLC, Cantor Fitzgerald & Co.
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100.5MraisedNov 2019 · 28 investors · BiotechnologyRule 506(b)
- MICHAEL MARTINDirector
- TODD BRADYDirector
- EDWARD KAYEDirector
- RODERICK WONGDirector
- NOREEN HENIGDirector
- TROY WILSONDirector
- SARAH BOYCEExecutive Officer, Director
- Offering amount
- $103.8M
- Amount sold
- $100.5M
- Sales commissions
- $2.7M
- Placement agents
- SVB Leerink LLC
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$18MraisedJan 2017 · 21 investors · BiotechnologyRule 506(b)
- Troy Wilson PhD., JDExecutive Officer, Director
- P. Kent HawrylukExecutive Officer
- Todd BradyDirector
- Michael Martin PhD.Director
- Offering amount
- $23.3M
- Amount sold
- $18M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$9.1MraisedFeb 2014 · 36 investors · BiotechnologyRule 506(b)
- Mark E. DavisDirector
- Frank McCormickDirector
- P. Kent HawrylukExecutive Officer
- Troy WilsonExecutive Officer, Director
- Offering amount
- $9.1M
- Amount sold
- $9.1M
- First sale
- Jan 2014
- Incorporated
- Limited Liability Company, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Avidity Biosciences went on to found or lead other companies.
Related companies · 3
Companies working in the same space as Avidity Biosciences.
Frequently asked questions
- What does Avidity Biosciences do?
- Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases. The company has three clinical-stage programs targeting myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.
- Who founded Avidity Biosciences?
- Avidity Biosciences was founded by Troy Wilson PhD., JD, P. Kent Hawryluk, Mark E. Davis, Troy Wilson in 2012.
- Who are Avidity Biosciences's investors?
- Avidity Biosciences's investors include Avoro Capital Advisors, Brace Pharma, F-Prime Capital, Frazier Life Sciences, Moore Venture Partners.
- How much funding has Avidity Biosciences raised?
- Avidity Biosciences has disclosed $527.8M raised across 4 of its 6 known rounds.
- Where is Avidity Biosciences headquartered?
- Avidity Biosciences is headquartered in La Jolla, US.